REG - Shield Therapeutics - Grant of Share Options

Shield TherapeuticsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9417Ca&default-theme=true

RNS Number : 9417C  Shield Therapeutics PLC  05 May 2026

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Grant of Share Options

 

London, UK, 05 May 2026: Shield Therapeutics plc (LSE: STX), a commercial
stage pharmaceutical company specialising in iron deficiency, announces that
on 04 May 2026 it granted share awards in the form of options over ordinary
shares in the capital of the Company ("Ordinary Shares") under Shield
Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group's
Chief Executive Officer ("CEO").

 

The following options have been granted to Anders Lundstrom, CEO, who is
deemed a PDMR:

 

 Name              Option Plan  Number of Ordinary Shares under Option  Vesting Date
 Anders Lundstrom  RPSP         5,162,294                               Three years from date of grant, subject to Mr Lundstrom remaining in office as

                                       at the date of vesting.

 

The proportion of total options awarded to Anders Lundstrom is approximately
0.48% of the total number of AIM securities in issue at this time.

 

Anders Lundstrom currently holds 585,000 ordinary shares in the Company.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Anders Lundstrom
 2.  Reason for the notification
 a)  Position/status                          Chief Executive Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Shield Therapeutics plc
 b)  LEI code                                 213800G74QWY15FC3W71
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over new Ordinary Shares

     Identification code

                                              ISIN: GB00BYV81293
 b)  Nature of the transaction                Grant of awards over new Ordinary Shares under the Company's Retention and
                                              Performance Share Plan.
 c)  Price(s) and volumes(s)                  2026 RPSP Award

Price (£)   Volume
                                              0.079       5,162,294

 
 d)  Aggregated information

     -  Aggregate volume                      Awards granted over 5,162,294 shares in total

     -  Price                                 7.9p exercise price

 e)  Date of the transaction                  04 May 2026
 f)  Place of the transaction                 Outside of trading venue

 

d)

Aggregated information

-  Aggregate volume

-  Price

 

 

Awards granted over 5,162,294 shares in total

7.9p exercise price

e)

Date of the transaction

04 May 2026

f)

Place of the transaction

Outside of trading venue

 

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations
 https://shieldtherapeutics.com/link/PRVKBP
 (https://shieldtherapeutics.com/link/PRVKBP)

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel                                                                                    +44 (0)20 7418 8900

 Joint Broker

 Cavendish Ltd

 Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet                                                   +44 (0)20 7220 0500
 Ward

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients and is now the leading #1
branded prescription oral iron the market today (data source - IQVIA Xponent
PlanTrak).

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. to include pediatric patients 10 years of age
and older with an exclusive, multi-year collaboration agreement with Viatris.
Outside of the U.S., the Company has licensed the rights to five specialty
pharmaceutical companies. FeRACCRU® is commercialised in the UK and European
Union by Norgine B.V., to include pediatric patients 12 years of age and older
and also have marketing rights in Australia and New Zealand. FeRACCRU® is
also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an
exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China,
Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of
Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc.
for Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUSARRNAUVRUR



            Copyright 2019 Regulatory News Service, all rights reserved